Home / Transcripts / Electromed, Inc. (ELMD) · May 12, 2026

Electromed, Inc. (ELMD) Earnings Call Transcript & Summary

May 12, 2026

NYSE American US Health Care Health Care Equipment and Supplies earnings 24 min

What were the key takeaways from Electromed, Inc.'s May 12, 2026 earnings call?

In the third quarter of fiscal 2026, Electromed, Inc. (ELMD) reported revenue of $18.6 million, reflecting an 18.4% year-over-year increase, and a diluted EPS of $0.35, up 67% from the prior year. The strong performance was driven by broad-based growth across segments, particularly a 43% increase in hospital revenue. Management maintained a positive outlook, indicating continued double-digit revenue growth potential, although they noted that recent growth rates may not represent a new normal.

What topics did Electromed, Inc. cover?

What were Electromed, Inc.'s May 12, 2026 results?

Electromed's strong Q3 results and strategic focus on the bronchiectasis market position the company favorably for future growth. Key catalysts include the expansion of their sales force, successful implementation of the ePrescribe solution, and increased payer coverage. However, investors should monitor the sustainability of growth rates and the effectiveness of their educational initiatives.

Earnings Call Speaker Segments

Mike Cavanaugh executive
#1

Good afternoon, and thanks for being on the Electromed earnings call. Electromed, Inc. put out its financial results for fiscal 2026's third quarter earlier today. You can find that press release right now on the company's site, www.smartvest.com. Before we begin, I want to remind all of you that a number of the remarks management makes during this call count as forward-looking statements, among them statements regarding the company's future operating and financial results and plans. Risks and uncertainties apply to such statements, and those could lead actual performance or achievements to differ materially from what has been projected. Statements of that kind reflect management's expectations only as of today's date. Please don't place undue reliance on them, and the company assumes no obligation to update or revise forward-looking statements, whether from new information, future events, or otherwise. For additional guidance on this subject, please consult the company's SEC filings. With me today are Jim Cunniff, Electromed's President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer. As on prior calls, Jim will walk through operational highlights from the quarter. Brad will follow with a review of the financials, and we'll wrap up with a question-and-answer session; so with that, I'll hand the call over to Jim Cunniff, President and Chief Executive Officer of Electromed.

Jim Cunniff executive
#2

Good afternoon, everyone, and thank you for being with us today. I'm glad to discuss our third quarter results. Let me begin with the key points. Q3 represents our 14th straight quarter in which revenue and profit both grew year over year. Revenue came in at $18.6 million, which is 18.4% growth versus the prior year. That performance shows how strong our commercial execution is and reflects growing recognition of SmartVest as the top solution for airway clearance. Growth spanned our entire business. Our flagship home care segment rose a robust 19%. Distributor revenues were up 3%, fueled by steady demand from our DME partners. Hospital climbed 43% over prior year and bounced back following a slow second quarter. The fact that we're growing across so many areas speaks to both the strength of our place in the market and how well our multi-channel approach is working. What's even more striking is the record profit we posted. In the third quarter, operating income climbed to $3.8 million — that's 76% higher than the same period a year ago. Diluted earnings per share came in at $0.35, which is 67% above the prior year. Turning to the balance sheet, we maintained a solid cash position totaling $17 million. You may recall that during the first quarter, our board gave the green light to a $10 million stock repurchase authorization — a sign of our belief that putting money into Electromed makes good sense. During Q3, we dialed back our buyback activity as we evaluate what's been happening in the broader macro market. Our dedication to identifying ways to deliver value back to shareholders remains unchanged. When you examine the numbers we posted, it's evident that the approach Electromed has established is performing effectively. Our dedication to airway clearance within the home care sector, paired with our capable sales and fulfillment groups—who manage everything from the prescription through to getting the vest delivered to the patient's residence—creates a distinct advantage for us in the marketplace. This way of operating gives us a solid base to keep expanding going forward. We've often noted that bronchiectasis frequently goes undiagnosed, and airway clearance is not prescribed as often as it should be. With that in mind, allow me to shift to what I consider the most thrilling aspect of our narrative: the bronchiectasis market that remains inadequately served. For Electromed, this stands as the key strategic opening that we are working hard to seize. The figures themselves make a persuasive case. On today's call, roughly 923,000 people across the United States have a bronchiectasis diagnosis, and just 16% of them are getting the benefit of high-frequency chest wall oscillation therapy right now. Let that sink in. Close to 800,000 patients with a diagnosis could be gaining the transformative advantages that our SmartVest system delivers, yet they aren't on this therapy at present. Just as striking, an estimated 4 million-plus others may be walking around with bronchiectasis that hasn't been diagnosed. What that tells us is that beyond a substantial business opportunity, there's a real need to keep educating people and raising awareness about this condition. To capture that opportunity, Electromed introduced its novel Triple Down on Bronchiectasis campaign, which champions a potent three-part treatment approach that is reshaping the way clinicians approach bronchiectasis management. To start, Clear Airways First using SmartVest is meant to clear out mucus effectively, since that mucus serves as fuel for infections down the road. Next, you address the patient's infection through antibiotics. Then, the third step involves aiding in the reduction of inflammation. The purpose here is to break a cycle we call the vicious vortex: ongoing infection, unrelenting inflammation, and airway damage continuously reinforce one another, and that process pushes forward progressive lung disease while lowering patients' quality of life. Results are coming from that campaign. Our Clear Airways First digital campaign has now been active for a year and a half, generating more than 2 million impressions and driving over 65,000 visits to our educational landing pages. We're reaching clinicians in the settings where they already work, and we're changing how bronchiectasis treatment gets discussed. At the same time, our clinical team is making an impact out in the field. Just in Q3, they gave presentations at four regional respiratory conferences, where they promoted the ABCs of bronchiectasis — Always be clearing the airways first with SmartVest. Peer-to-peer education is also delivering results. We ran four virtual webinars with well-regarded pulmonologists, and more than 375 clinicians joined those sessions. Peer-to-peer conversations about SmartVest's clinical advantages carry real weight with physicians. At important conferences, our footprint keeps growing. During the quarter, members of the SmartVest team were present at three national gatherings, which keeps us in front of and in dialogue with the specialists in bronchiectasis who come together at those events. Beyond that, we've been conducting meaningful research aimed at pinpointing where patient care falls short; a manuscript we finished, drawing on data from the NTM Bronchiectasis Research Registry, revealed that HFCWO therapy went unprescribed for 58% of patients who qualified, even though they met the clinical criteria. That shortfall points to a clear opening for stepping in sooner, and our team is pushing hard to eliminate it — partly by way of our Sip On This campaign, which is designed to spark dialogue with pulmonologists who diagnose a high volume of bronchiectasis but have not started prescribing HFCWO. Alongside clinical education, we're pursuing innovation in both technology and process so that prescribing SmartVest becomes simpler for clinicians and patients can begin therapy sooner. Our Smart Order ePrescribe tool is changing the way clinics send orders to our fulfillment team. The timing here matters, since CMS has just finalized new regulations that require covered entities to update how they handle orders and stop using faxes by May 2028. Our ePrescribe offering is already compliant with CMS rules on electronic signatures and order processing, so we're ahead of where the industry is heading. Launching ePrescribe has gone well. During Q3, more than 40% of orders flowed through our Smart Order product, and that cut average days to ship by five days compared with fax orders. Prescriptions handled by this system should only grow in number; the upshot is faster therapy for patients and better workflow for clinics. Boosting payer coverage continues to be a key strategy so patients can take advantage of our technology. Good news: contracts now cover 86% of covered lives in the U.S. who might benefit from SmartVest. The covered lives we've added over the past 18 months have resulted in over 50 referrals where we would have otherwise not been able to recognize revenue. Every single one of those stands for a patient whose life is something we can make better. Turning to the commercial side, we closed out Q3 with 58 direct sales reps. That figure is flat compared with the second quarter, yet I'm pleased to share that four more sales reps have joined our roster since then, bringing us to 62 and maximizing the coverage of our market. Before handing things to Brad, I'd like to briefly address our operational capabilities, which represent yet another major competitive advantage, particularly in the current environment. Last year we launched a manufacturing optimization plan, and it's now finished. We rearranged our plant physically, which lets our production process run better and gives us room to grow later on. It's a particular point of pride for me that the Made in the USA label appears on what we make. Electromed is headquartered in America, with our operations and product assembly located here at home, and 99% of net revenues come from within the United States. Risks definitely do exist, but we've sustained our strong on-time delivery record with customers and held onto our solid gross margins, all while global conditions remain uncertain. With that said, I'd like to pass the call to Brad so he can review our financials. Brad, the floor is yours.

Brad Nagel executive
#3

Every figure I'll be going over relates to the quarter that closed on March 31st, 2026 — our Q3 of fiscal 2026 — and is set against the quarter that closed on March 31st, 2025, which was Q3 of fiscal 2025. Net revenues climbed 18.4%, reaching $18.6 million, up from $15.7 million. Within the direct home care business, revenue rose 18.6%, hitting $16.7 million versus $14.1 million. That revenue gain came mainly from having more direct sales representatives as well as better net revenues for each sales rep. Across Q3, our home care direct field sales representatives numbered 57 on average. For Q3, annualized home care revenue per weighted average direct sales representative came to $1,168,000, which beat the $1 million-$1.1 million target range for a second quarter in a row. Non-home care revenue totaled $1.8 million. Hospital revenue was up 42.5%, amounting to $1.0 million. Home care distributor re-revenue came in at $0.7 million, a rise of 2.7%. Other revenue, at $0.1 million, fell 40.7%. Gross profit rose year-over-year to $14.6 million, or 78.8% of net revenues, from $12.2 million, or 78.0% of net revenues. Those gains in gross profit dollars and gross profit percentage stemmed mainly from higher overall revenue and greater net revenues per device. Selling, general, and administrative, or SG&A, expenses totaled $10.5 million, which was $0.7 million higher, or up 7.2%. This period's increase largely reflected greater salaries and incentive compensation tied to a larger average sales headcount and higher overall compensation costs. Operating income reached $3.8 million, or 20.3% of net revenues, versus $2.1 million, or 13.6% of net revenues. That 76% jump in operating income resulted mainly from the gains in revenue and gross profit. Net income rose 58.8% to $3 million, or $0.35 per diluted share, compared with $1.9 million, or $0.21 per diluted share. On March 31st, 2026, Electromed held $17 million in cash along with $28.3 million in accounts receivable and carried no debt, which put working capital at $40 million and total shareholders' equity at $49.2 million. The cash balance represents a $1.7 million increase across the nine months ended March 31st, 2026, against a $0.8 million cash decrease across the nine months ended March 31st, 2025. What drove the cash increase over the nine months ended March 31st, 2026 was mainly positive operating cash flow of $6.7 million, partly offset by $3.9 million of share repurchases of Electromed common stock. Although Q3's growth rates — 18% for revenue and 76% for operating income — mark recent quarterly highs rather than a new normal expectation, we stay confident in our capacity to keep delivering double-digit revenue growth along with expanded operating leverage as we wrap up fiscal year 2026 and keep helping more patients to breathe easier into the future. With that, we'd like to move to the Q&A portion of the call. Operator, please open the call to questions.

Kyle Bauser analyst
#4

Hey Jim and Brad. I appreciate you both fielding my questions, and congratulations on yet another very strong quarter. It seems like one big factor behind the impressive revenue increase has been the people you've brought on board, and I realize new sales reps need time to get up to speed, yet you still came in above the range you were targeting. Have you been opening up new territories or regions, or splitting the ones you already have down the middle? I'm just curious about the way you've been bringing reps on board.

Jim Cunniff executive
#5

Kyle, it's nice to hear from you, and I appreciate the question. As we mentioned in our prepared remarks, we averaged roughly 57 reps during the quarter that just ended. With such solid results, credit really goes to the reps we had out in the field, along with the fact that we enjoyed some favorable tailwinds on the insurance side of our mix, which certainly gave revenue a lift. That said, we finished the quarter sitting at 58 reps. As I've been saying throughout the year, our plan was to reach 61 territories by the close of our fiscal year; we've now got 62 territories staffed; and we're actually beginning to bring reps on board as Q4 wraps up and we turn our attention toward what's ahead in our next fiscal year. Looking at that next fiscal year, we expect to bring on somewhere around four to five more reps, and that process is already underway.

Kyle Bauser analyst
#6

All right, thanks for that; that was actually going to be my next question, which was roughly what's the ceiling when it comes to headcount? Thanks for that. For my next question, I suppose, do you still think BRINSUPRI has been a net positive for SmartVest, considering the greater awareness surrounding bronchiectasis and what that has been able to accomplish?

Jim Cunniff executive
#7

Yes, we do. You know, I believe the main point for everyone listening to keep in mind is that bronchiectasis is a disease that is chronic and irreversible. Of course, you know, from our perspective, the drug targets inflammation, which forms part of that vicious vortex I brought up earlier on the call. Essentially, you know, these patients have mucus accumulating in their airways, and they require something that can clear out that mucus, which serves as the future fuel for future infections. That's really the role we play. You know, we're a piece of that care continuum in which we're the ones actually clearing the mucus. The BRINSUPRI drug is assisting in tackling inflammation, and that's really in order to stabilize the inflammation. Certainly, the drug has served as a tailwind because of greater patient and provider awareness, you know, which has been terrific, I believe, and it has lifted all boats in this market. The drug is an adjunct; it does not replace SmartVest. You know, that's further validated by the fact that although the guidelines have not been published by CHEST, it has actually issued preliminary guidelines, and airway clearance is part of the care continuum. I think that's quite promising. We're waiting for those results to be published; those are really meant to help give clinicians some guidelines regarding how to treat bronchiectasis patients. Up to now, there really haven't been any industry-wide guidelines here in the U.S. to treat bronchiectasis patients, and we're excited about that.

Kyle Bauser analyst
#8

All right, understood. No, that's useful. Thanks for that. Congratulations once more on the results, especially on the earnings growth. I'll get back in line.

Jim Cunniff executive
#9

Thank you, Kyle.

Ben Haynor analyst
#10

Hello, everyone, and thank you for taking my questions this afternoon. To start, regarding the newly hired sales representatives, could you refresh our memory on the usual timeline for someone to become fully productive in a new territory? Also, are any of these individuals stepping into territories that already existed but where there had been departures, whether those were voluntary or involuntary?

Jim Cunniff executive
#11

Sure. That question really breaks down into a couple of pieces. Typically, it takes somewhere between four and six months to ramp up, Ben Haynor. We're clearly constantly exploring ways to shorten that period, though it's a fairly solid sign of the amount of time needed for someone to find their footing and, you know, become familiar with this marketplace and with the new customers they'll be serving. If you consider the 61 reps we had planned on for this year, a portion of those were extension territories tied to fiscal year 2026. That said, we currently sit at 62 reps, and as we look ahead to next year, our plan is to bring on four to five more territories. Right now we're at 62, and that process is already underway; we're genuinely enthusiastic about it. So during the quarter that just ended, a few individuals on our team did decide to retire, and that's the sort of thing you can't really plan for. Naturally, there's always going to be some turnover in a sales organization, but what matters to us is keeping every territory staffed, since this remains mostly a clinical sale—you need reps out in the field engaging with pulmonologists and finding patients who could benefit from our technology. In our view, our reps perform exceptionally well at that.

Ben Haynor analyst
#12

All right, that's useful. So then, taking into account ABC — Always Be Closing — plus those 375 clinicians you said were in attendance and all the different events you run, can you in some way determine or put a number on when and if they eventually write prescriptions?

Jim Cunniff executive
#13

Yeah, I mean, we do monitor that. Much of it at this point is simply awareness. Part of what we have not managed to quantify is, you know, out of those 375 people who took part in, say, a few of the peer-to-peer educational conferences, what does the conversion rate look like? Frequently it's the case that, you know, a number of these clinicians — and that can include a combination of pulmonologists along with other specialties — are in many instances truly being introduced to this disease state, along with the various treatment choices available. You know, we are assisting in building that awareness, on top of the drug that was recently brought to market, plus some of our other competitors in the space. ATS, which is among the big conferences on the calendar, is in fact taking place, you know, this week — that gives us another chance to reach clinicians who are mainly on the clinical side, the ones conducting studies, and so on. We're quite enthusiastic about continuing to showcase our product technology and the impact it can have on patients' lives, and about giving them awareness of our product.

Ben Haynor analyst
#14

Great, that's useful. I appreciate you gentlemen answering our questions, and congratulations on the quarter.

Jim Cunniff executive
#15

Thanks.

Jim Cunniff executive
#16

Thanks, operator. So for all of you listening in, to sum things up, during our third fiscal quarter Electromed has every cylinder firing. We turned in robust financial performance and we're carrying out our plan against the bronchiectasis opportunity, which remains largely untapped, with purpose and precision. Our team stays focused, the strategy we've chosen is delivering, and there's considerable runway still in front of us. I want to express gratitude to our outstanding team for their commitment, to our customers for placing their trust in us, and to our shareholders for standing by us. We're eager to keep building on this momentum as the coming quarters unfold. And with that, thanks to all of you.

Operator operator
#17

Everyone, we appreciate you joining. That brings today's call to a close. Please feel free to hang up, and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Electromed, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Electromed, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.